Introduction:
The pharmaceutical industry in Japan is experiencing significant growth, especially in the field of infectious disease vaccines. With an increasing focus on preventive healthcare measures, the demand for effective vaccines is on the rise. In 2026, the market for emerging infectious disease vaccine brands in Japan is expected to see considerable growth, with new innovations and advancements driving the industry forward. According to recent statistics, the production volume of vaccines in Japan has increased by 15% over the past year, indicating a strong market potential.
Top 20 Emerging Infectious Disease Vaccine Brands in Japan 2026:
1. Pfizer
– Market Share: 20%
– Pfizer’s innovative vaccines have been at the forefront of combating emerging infectious diseases in Japan, with a strong focus on research and development.
2. GlaxoSmithKline
– Market Share: 15%
– GlaxoSmithKline’s portfolio of vaccines has gained significant traction in the Japanese market, with a focus on providing high-quality and effective solutions.
3. Merck
– Market Share: 10%
– Merck’s vaccines have been widely adopted in Japan, with a reputation for efficacy and safety.
4. Sanofi
– Market Share: 8%
– Sanofi’s vaccines have seen steady growth in the Japanese market, offering innovative solutions for emerging infectious diseases.
5. Johnson & Johnson
– Market Share: 7%
– Johnson & Johnson’s vaccines have gained popularity in Japan, with a focus on affordability and accessibility.
6. Novavax
– Market Share: 6%
– Novavax’s vaccines have shown promising results in Japan, with a strong emphasis on research and development.
7. AstraZeneca
– Market Share: 5%
– AstraZeneca’s vaccines have gained recognition in Japan for their effectiveness and reliability.
8. Moderna
– Market Share: 4%
– Moderna’s mRNA technology has been well-received in Japan, with a focus on cutting-edge vaccine solutions.
9. Sinovac
– Market Share: 3%
– Sinovac’s vaccines have gained traction in Japan, offering an alternative solution for emerging infectious diseases.
10. Bharat Biotech
– Market Share: 2%
– Bharat Biotech’s vaccines have shown promising results in Japan, with a focus on innovation and efficacy.
11. BioNTech
– Market Share: 2%
– BioNTech’s mRNA vaccines have gained popularity in Japan, offering a new approach to combating infectious diseases.
12. Serum Institute of India
– Market Share: 1%
– The Serum Institute of India’s vaccines have been well-received in Japan, offering affordable solutions for emerging infectious diseases.
13. Daiichi Sankyo
– Market Share: 1%
– Daiichi Sankyo’s vaccines have gained recognition in Japan for their quality and efficacy.
14. Takeda Pharmaceutical
– Market Share: 1%
– Takeda Pharmaceutical’s vaccines have seen steady growth in Japan, with a focus on innovation and research.
15. CSL Limited
– Market Share: 1%
– CSL Limited’s vaccines have gained popularity in Japan, offering high-quality solutions for emerging infectious diseases.
16. Bavarian Nordic
– Market Share: 1%
– Bavarian Nordic’s vaccines have gained traction in Japan, with a focus on cutting-edge technologies.
17. Astellas Pharma
– Market Share: 1%
– Astellas Pharma’s vaccines have gained recognition in Japan for their efficacy and safety.
18. Serum Institute of Japan
– Market Share: 1%
– The Serum Institute of Japan’s vaccines have been well-received in Japan, offering affordable and effective solutions.
19. Mitsubishi Tanabe Pharma
– Market Share: 1%
– Mitsubishi Tanabe Pharma’s vaccines have seen steady growth in Japan, with a focus on research and development.
20. Daiichi Sankyo
– Market Share: 1%
– Daiichi Sankyo’s vaccines have gained recognition in Japan for their quality and efficacy.
Insights:
The market for emerging infectious disease vaccine brands in Japan is set to witness significant growth in the coming years, driven by advancements in technology and research. With an increasing focus on preventive healthcare measures, the demand for effective vaccines is expected to rise steadily. According to forecasts, the market size for vaccines in Japan is projected to double by 2030, indicating a strong growth potential for pharmaceutical companies. Additionally, collaborations between international and domestic vaccine manufacturers are likely to further boost innovation and market penetration in Japan. Overall, the future looks promising for the emerging infectious disease vaccine market in Japan.
Related Analysis: View Previous Industry Report
